LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling [Corrigendum]
Wang Q, Liao J, He Z, et al. Onco Targets Ther. 2020;13:10983–10994
The Corrigendum notice (https://www.dovepress.com/corrigendum-lhx6-affects-erlotinib-resistance-and-migration-of-egfr-mu-peer-reviewed-article-OTT) that was published January 12, 2021 was incorrect. The authors have advised on page 10993, Funding section, “This study was supported by grants from the Natural Science Foundation of Fujian Province (grant nos. 2017J01261 and 2016JD1488)” should have been “This study was supported by grants from the Startup Fund for Scientific Research, Fujian Medical University (grant no. 2017XQ1217), Joint Funds for the Innovation of Science and Technology, Fujian Province (grant no. 2017Y9080), and Fujian Provincial Sci & Tech Guiding Project (grant no. 2018Y0017).”
The authors apologize for this error.
Read the original article
Previous corrigendum has been published
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]